What GLP-1 actually is
GLP-1 stands for glucagon-like peptide-1. It is not a drug — it is a hormone your own body produces. Understanding the natural hormone is the key to understanding everything the medications do, because the drugs are, in essence, an amplified imitation of it.
GLP-1 is released by the gut after you eat. It belongs to a family of hormones called incretins, and it has several jobs that together help the body manage food and energy. It prompts the pancreas to release insulin when blood sugar rises, which is why it matters so much in diabetes. It slows the rate at which the stomach empties, so food stays with you longer. And it acts on the appetite centres of the brain to increase the feeling of fullness and reduce hunger.
In other words, GLP-1 is part of the body's natural system for regulating appetite and blood sugar. The medications work by borrowing that system and turning up the volume.
How the medications work
GLP-1 medications are known technically as GLP-1 receptor agonists. An agonist is simply something that activates a receptor — so these drugs bind to the same receptors the natural hormone would, and switch them on, but far more powerfully and for much longer than the body's own short-lived GLP-1 does.
The effect is a sustained version of what the natural hormone does briefly after a meal. Appetite falls. Fullness arrives sooner and lasts longer. The near-constant background hum of hunger and food cravings that makes calorie restriction so hard for most people is quietened. People eat less, not through willpower or deprivation, but because the biological signals driving them to eat have been turned down.
This is the crucial distinction from old-fashioned appetite suppressants. GLP-1 drugs are not stimulants forcing the body to ignore hunger. They are working at the level of the hormones that generate hunger in the first place, which is why the reduction in appetite feels, to many people, less like a battle and more like the noise simply being turned off. It is also why the main side effects cluster in the digestive system — the same slowed stomach-emptying that keeps you full can, especially early on, cause nausea.
The naming, decoded
Nothing about GLP-1 medicines confuses people more than the names. The same drug can have two brand names; different drugs get lumped together; and "Ozempic" has become a generic shorthand for a whole category it is only one member of. Here is the map.
There are two active ingredients that dominate the conversation, each sold under different brand names for different purposes.
Semaglutide is the first. As a weekly injection, it is sold as Ozempic (licensed for type 2 diabetes) and as Wegovy (licensed, at higher doses, for weight loss). It is the same molecule in both — the brand and dose differ according to what it is approved to treat. Semaglutide also now exists as a daily tablet: Rybelsus (a lower-dose pill for diabetes) and, more recently, a higher-dose oral version of Wegovy for weight loss.
Tirzepatide is the second, and newer. It is sold as Mounjaro (for diabetes) and Zepbound (the weight-loss brand used in some countries). Again, the same molecule under two names.
Then there are the older and newer members. Liraglutide (sold as Saxenda for weight loss and Victoza for diabetes) is an earlier, daily-injection GLP-1, generally less potent than the newer options. And a new generation of oral drugs from other manufacturers is arriving, designed to compete with the semaglutide pill.
The single most useful thing to hold onto: Ozempic and Wegovy are the same drug (semaglutide); Mounjaro and Zepbound are the same drug (tirzepatide). The different names reflect different licensed uses and doses, not different medicines. Even clinicians report patients asking to switch from one to a brand that turns out to be identical.
| Active ingredient | Brand name | Licensed use | Format |
|---|---|---|---|
| Semaglutide | Ozempic | Type 2 diabetes | Weekly injection |
| Semaglutide | Wegovy | Weight loss (obesity) | Weekly injection |
| Semaglutide | Rybelsus | Type 2 diabetes | Daily tablet |
| Semaglutide | Wegovy (oral) | Weight loss (obesity) | Daily tablet |
| Tirzepatide | Mounjaro | Type 2 diabetes | Weekly injection |
| Tirzepatide | Zepbound | Weight loss (obesity) | Weekly injection |
| Liraglutide | Victoza | Type 2 diabetes | Daily injection |
| Liraglutide | Saxenda | Weight loss (obesity) | Daily injection |
Single, dual, and triple agonists
If you take one concept from this guide that explains why some of these drugs are more powerful than others, it is this one.
The original GLP-1 drugs, semaglutide among them, target a single receptor — the GLP-1 receptor. They are single agonists. They work, and they work well.
Tirzepatide (Mounjaro/Zepbound) does something more. It is a dual agonist: it activates the GLP-1 receptor and a second one, the GIP receptor. GIP is another gut hormone involved in insulin release and fat metabolism, and targeting both pathways at once appears to produce a broader metabolic effect — which is the leading explanation for why tirzepatide tends to produce greater weight loss than semaglutide in trials. Adding a second hormonal signal amplifies the result.
The logic doesn't stop at two. A triple agonist — targeting GLP-1, GIP, and a third hormone, glucagon — is in advanced development, and early trial results have shown the largest weight reductions reported for any obesity medication so far. The clear trend across the field is that hitting more of the body's metabolic pathways at once tends to produce stronger effects, and the newest drugs are pushing in exactly that direction.
This single-versus-dual-versus-triple distinction is the backbone of how the different medicines compare on effectiveness — which our comparison blog covers in detail with the specific trial figures.
| Type | Receptors targeted | Example drug(s) | Relative effect |
|---|---|---|---|
| Single agonist | GLP-1 | Semaglutide (Ozempic, Wegovy), Liraglutide (Saxenda, Victoza) | Established, substantial weight loss and glucose control |
| Dual agonist | GLP-1 + GIP | Tirzepatide (Mounjaro, Zepbound) | Greater weight loss than single agonists in head-to-head trials |
| Triple agonist | GLP-1 + GIP + glucagon | Retatrutide (in development) | Largest reductions reported for any obesity drug so far |
From injection to pill
For most of their history, these drugs shared one practical drawback: they were injections. Effective, but off-putting for the significant number of people wary of needles, or unwilling to deal with weekly self-injection and refrigerated pens.
That is changing. Semaglutide is now available as a daily tablet, both in the long-standing lower-dose diabetes form (Rybelsus) and, more recently, as a higher-dose oral version for weight loss. There is a genuine pharmaceutical challenge behind this: the stomach is designed to break down proteins like semaglutide before they can be absorbed, which is why these drugs were injectable in the first place. The oral versions have to be formulated to survive that environment, and taken under strict conditions — on an empty stomach, with only plain water, waiting before eating — for the drug to be absorbed at all.
The oral versions expand access considerably, removing the needle barrier for people who found it a genuine obstacle. But they come with their own trade-offs — a demanding daily routine, and somewhat different tolerability — so a tablet is not automatically the better choice over an injection. It is simply a different one.
Beyond weight loss: the expanding uses
It is easy to think of these as weight-loss drugs, but that is arguably the newest chapter of a longer story — and the list of things they treat is growing rapidly.
They began as diabetes medicines, and that remains a core use: by prompting insulin release when blood sugar is high, they improve blood-glucose control in type 2 diabetes, which is what Ozempic and Mounjaro are primarily licensed for.
Their cardiovascular benefits have since been established in large trials: semaglutide has been shown to reduce the risk of major adverse cardiovascular events — heart attack, stroke, cardiovascular death — in certain high-risk groups, a genuinely significant finding that extends their value well beyond weight.
More recently, semaglutide gained approval for MASH (metabolic dysfunction-associated steatohepatitis), a serious form of fatty liver disease, in people with significant liver scarring. Tirzepatide has been approved for obstructive sleep apnoea in adults with obesity. And researchers are actively investigating a long list of other potential applications, from addiction to neurodegenerative disease.
The through-line is that GLP-1 affects far more of the body than appetite alone. As the research matures, these are looking less like weight-loss drugs that happen to have other effects, and more like broad metabolic medicines whose weight-loss effect is one benefit among several.
| Condition | What the drug does | Status |
|---|---|---|
| Type 2 diabetes | Prompts insulin release when blood sugar is high; improves glucose control | Established, licensed use |
| Cardiovascular risk (high-risk groups) | Reduces risk of heart attack, stroke and cardiovascular death | Established in large trials (semaglutide) |
| MASH (fatty liver disease) | Improves liver inflammation and reduces disease progression | Approved (semaglutide) in people with significant scarring |
| Obstructive sleep apnoea | Reduces severity in adults with obesity | Approved (tirzepatide) |
| Chronic kidney disease | Slows decline in kidney function in high-risk patients | Trial evidence emerging |
| Addiction & neurodegenerative disease | Signals of reduced cravings; possible neuroprotective effects | Under active investigation |
What happens when you stop
This is one of the most important and least understood aspects of the entire class, and it follows directly from how the drugs work.
Because GLP-1 medications suppress appetite pharmacologically, their effect lasts only as long as they are taken. When the drug stops, the appetite-regulating signals return to their previous state — and for most people, so does the appetite, and with it the weight. Large analyses have found that people regain a substantial proportion of lost weight within a year of stopping, and that the improvements in blood sugar, blood pressure, and cholesterol seen during treatment also tend to drift back toward where they started.
This is not a sign the drugs don't work. It reflects what they are: a treatment for an ongoing condition, not a short course that fixes something permanently. In that sense they are more like blood-pressure medication — which controls the problem while taken rather than curing it — than like a course of antibiotics.
The practical implication is significant. These medicines work best not as a standalone intervention but as part of a broader, lasting change in eating patterns, activity, and relationship with food — the things that support maintaining weight loss when and if the medication stops. The best real-world outcomes consistently come from combining the drug with that kind of durable behavioural foundation, which is exactly where structured programmes have their value.
Side effects and safety, in brief
A full account of side effects belongs with a prescriber and the patient information leaflet, but the broad picture is worth knowing.
By far the most common side effects are gastrointestinal — nausea, vomiting, diarrhoea, and constipation — driven by the same slowed stomach-emptying that produces the fullness. These are usually most pronounced when starting the drug or increasing the dose, and often ease over time, which is why prescribers start low and increase gradually. Rarer but more serious risks include pancreatitis and gallbladder problems, and dehydration-related effects on the kidneys.
There is also an important point about what is lost: rapid weight loss on these drugs includes some muscle alongside fat, which is why adequate protein intake and resistance exercise matter throughout treatment to preserve lean tissue. And the drugs are not suitable for everyone — they are not used in pregnancy, and certain personal or family medical histories rule them out.
The overarching safety point is simple: these are prescription medicines requiring proper medical assessment and monitoring, not products to source and self-administer without oversight. The rise of a poorly regulated online market makes that worth stating plainly.
How to think about the whole category
Step back from the individual brands and a clearer picture emerges. GLP-1 medications represent a genuine shift in how medicine can treat obesity and several metabolic conditions — not by overriding the body, but by working with its own appetite- and glucose-regulating hormones, amplified and sustained.
They are highly effective for many people. They are increasingly varied — single, dual, and soon triple agonists; injections and tablets; a widening range of approved uses. And they are not magic: they work best alongside real lifestyle change, most people regain weight if they stop without that foundation, and they carry real side effects and require proper medical supervision.
If you are weighing up the specific weight-loss injections — which is most effective, what each costs, and how to access them in the UK — that is the natural next step, and we cover it in depth in our comparison. This guide's job was the foundation beneath that decision: understanding what this remarkable class of medicines actually is, and how it works.
Frequently Asked Questions
- What does GLP-1 stand for, and what is it?
- GLP-1 stands for glucagon-like peptide-1. It's a hormone your body produces naturally in the gut after eating. It helps regulate blood sugar by prompting insulin release, slows how quickly the stomach empties, and signals fullness to the brain. GLP-1 medications are receptor agonists — drugs that activate the same receptors as this natural hormone, but more powerfully and for longer.
- How do GLP-1 medications work?
- They mimic the natural GLP-1 hormone at higher, more sustained levels than the body produces on its own. This reduces appetite, brings on fullness sooner and for longer, and quietens food cravings — so people eat less without the constant hunger that makes dieting so hard. Because they also slow stomach emptying, the main side effects tend to be digestive, especially early on.
- Are Ozempic and Wegovy the same drug?
- Yes — both contain semaglutide. The difference is what they're licensed and dosed for: Ozempic is approved for type 2 diabetes, while Wegovy is approved, at higher doses, for weight management. Similarly, Mounjaro and Zepbound are both tirzepatide, branded differently for diabetes and weight loss. The active medicine is the same; the name reflects the approved use.
- What's the difference between a single, dual, and triple agonist?
- It refers to how many hormone receptors the drug activates. Older GLP-1 drugs like semaglutide target one receptor (single agonist). Tirzepatide targets two — GLP-1 and GIP — making it a dual agonist, which appears to produce greater effects. Triple agonists, targeting a third hormone (glucagon) as well, are in development and have shown the largest weight reductions reported so far. Broadly, targeting more metabolic pathways tends to produce stronger results.
- Do GLP-1 drugs treat anything other than weight loss?
- Yes — considerably more. They were originally developed for type 2 diabetes and remain a core treatment for it. Semaglutide has been shown to reduce the risk of major cardiovascular events in certain high-risk groups, and has gained approval for a serious form of fatty liver disease (MASH). Tirzepatide has been approved for obstructive sleep apnoea in adults with obesity. Research into further uses is ongoing.
- Do you regain weight after stopping GLP-1 medication?
- Usually, yes — most people regain a significant proportion of lost weight within a year of stopping, and the improvements in blood sugar, blood pressure, and cholesterol tend to drift back too. This is because the drugs suppress appetite only while taken; when they stop, appetite returns. They're best understood as a long-term treatment for an ongoing condition rather than a short course, and work best alongside lasting changes to diet and activity that help maintain the results.
Read next
- Weight Loss Injections UK: Mounjaro vs Wegovy vs Ozempic Compared — the detailed, UK-focused head-to-head, with effectiveness, cost, and access.
- The Wegovy Pill Arrives in the UK: What It Is and How It Works — a closer look at oral semaglutide.
- GLP-1 Drugs and Breast Cancer Risk: What the Evidence Shows
This guide is for education and general information. It is not medical advice, and GLP-1 medications are prescription-only. Always consult a qualified healthcare professional about whether they are appropriate for you.